Cargando…
Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics
RNA interference (RNAi)-based therapeutics have been used to silence the expression of targeted pathological genes. Small interfering RNA (siRNAs) and microRNA (miRNAs) inhibitor have performed this function. However, short half-life, poor cellular uptake, and nonspecific distribution of small RNAs...
Autores principales: | Gentile, Emanuela, Oba, Taro, Lin, Jing, Shao, Ruping, Meng, Feng, Cao, Xiaobo, Lin, Heather Y., Mourad, Majidi, Pataer, Apar, Baladandayuthapani, Veerabhadran, Cai, Dong, Roth, Jack A., Ji, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564640/ https://www.ncbi.nlm.nih.gov/pubmed/28637023 http://dx.doi.org/10.18632/oncotarget.18421 |
Ejemplares similares
-
TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin
por: Xiaobo, Cao, et al.
Publicado: (2016) -
Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
por: Pataer, Apar, et al.
Publicado: (2018) -
Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells
por: Pataer, Apar, et al.
Publicado: (2019) -
Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance
por: Hao, Chuncheng, et al.
Publicado: (2016) -
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
por: Cao, Xiaobo, et al.
Publicado: (2017)